$MRVI

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 exhibit991-q22026.htm EX-99 Document Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Second quarter 2026 total revenue up 9% from prior year SAN DIEGO, Calif., — August 6, 2026 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI),

Biotech stocks rose to 52-week highs on July 22, 2026 after positive updates. Medpace (MEDP) jumped over 77% to $677.90 on Q2 results, with GAAP net income of $121.4M and revenue up 17% to $707M. Novocure (NVCR) gained 28% to $20.55 on Q2 net revenues of $183.6M. Eton (ETON) and Maravai (MRVI) also hit highs; Advanced Biomed (ADVB) rose 36% to $20.87.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G reporting a shared voting and dispositive power over 7,228,864 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock, which represents a 4.9% stake. The filing indicates they had briefly exceeded 5% beneficial ownership on May 6, 2026, but were below that threshold by the filing date, with a Joint Filing Agreement dated May 11, 2026. This is a passive investment disclosure, as indicated by the use of Schedule 13G.

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of -33.33% and -18.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai ( MRVI ) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai ( MRVI ) To Contact Him Directly To Discuss Their Options

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of -33.33% and -2.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings ...

SAN DIEGO, July 28, 2025 ( GLOBE NEWSWIRE ) -- Maravai LifeSciences, Inc. ( Maravai ) ( NASDAQ: MRVI ) , a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2025 financial and operating results after the market close ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai ( MRVI ) To Contact Him Directly To Discuss Their Options